Home Companies Catalysts Deep Dives
Ninlaro ixazomib APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Launch2015-11-20
US LOE2029-01-01
Peak Sales Est$800M
Formulations[{"id":"ninlaro-po","route":"PO","setting":"OUTPATIENT","frequency":"Weekly (days 1, 8, 15 of 28-day
Companies
TAK (ORIGINATOR)100%
Mechanism: Proteasome inhibitor
Expert: Oral proteasome inhibitor targeting the 20S proteasome, inducing apoptosis in myeloma cells.
Everyday: Blocks cancer cells from disposing of damaged proteins, causing them to die.
Targets: ["PROTEASOME"]
Revenue History
PeriodRevenue ($M)
2024$780M
Programs (1)
IndicationStageKey StudyRegional Status
R/R MMAPPROVEDTOURMALINE-MM1[{"stage":"APPROVED","region":"US","approval_date":"2015-11-20"},{"stage":"APPRO
Notes
First oral proteasome inhibitor for multiple myeloma. Maintenance therapy after transplant. Mature product with modest growth.
Data from Supabase · Updated 2026-03-24